SK bioscience stock: Q3 loss narrows as IDT boosts recovery
Published on 11/13/2026 at 03:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRecovery rests on broader operations
- Third-quarter sales improved as IDT Biologika increased revenue and profit.
- SK bioscience is building medium-term growth around vaccines, CDMO services and pipeline development.
- GBP410 remains a key late-stage vaccine project with Sanofi.
SK bioscience said on Thursday, November 12, that third-quarter revenue rose 21 percent year over year to KRW 182.4 billion. The company also narrowed its operating loss by 42 percent to KRW 11.2 billion and swung to a pretax profit of KRW 6.1 billion, according to The Asia Business Daily.
IDT strengthens the recovery
IDT Biologika was the main earnings contributor. The German subsidiary increased third-quarter revenue 21 percent year over year to KRW 113.1 billion, while operating profit rose about 66 percent to KRW 9.6 billion. Higher production volumes, a larger share of high-margin sales and improved operating efficiency supported the result.
SK bioscience also benefited from increased shipments of its SKYVaricella chickenpox vaccine through the Pan American Health Organization. Distribution of Sanofi products, including the RSV preventive antibody Beyfortus and the six-in-one vaccine Hexaxim, added to the companys vaccine business.
Pipeline adds a longer-term driver
The company is developing GBP410, a 21-valent pneumococcal conjugate vaccine, with Sanofi. A global Phase 3 trial is under way in South Korea, the United States and Europe, with topline results expected in the second half of 2027.
SK bioscience has also expanded commercial production at its L HOUSE vaccine plant in Andong. It expects KRW 300 billion in long-term funding from the National Growth Fund to support research, commercialization preparations and production upgrades.
Business spans vaccines and manufacturing
SK bioscience develops and supplies vaccines, distributes licensed products and operates contract development and manufacturing activities through IDT Biologika. Its business reaches domestic and international markets, including vaccine supply programs in the Americas and manufacturing operations in Germany.
The company is broadening its portfolio beyond established vaccine sales through CDMO projects and clinical development. Its pipeline includes the RSV prevention antibody RSM01, while SK bioscience and IDT are also involved in Ebola and influenza vaccine programs with international partners.
SK bioscience at a glance
- Company: SK bioscience
- ISIN: KR7302440003
- Ticker: 302440.KS
- Business: Vaccines, vaccine distribution and contract development and manufacturing
- Key pipeline: GBP410 and RSM01
South Korean equities trade in the KOSPI market environment.
